Private Messaging App Launches on Quantum Resistant, Decentralized xx network
The world’s first quantum-resistant messaging app, xx messenger, launched on the xx network today. xx messenger allows users to communicate in real time through hundreds of decentralized nodes operating worldwide. The app is available for download on IOS and Android, features group chat as well as photo and audio sharing, and designed for easy use and switching to from legacy messaging apps.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220125005773/en/
David Chaum (Photo: Business Wire)
Unlike existing messaging apps, xx messenger uses quantum-resistant cryptography to protect message content from decoding and cMix software to obfuscate or shred metadata—information about who sends, when they send, where they send from, and who receives. Randomly selected teams of xx nodes encrypt anonymity sets of 1,000 messages, which are then repeatedly shuffled and have also been encrypted using quantum-resistant cryptography. Information that links senders and receivers is destroyed, preventing third parties from tracking intimate details about the patterns and structure of our lives.
Centralized service providers now surveil and profile the majority of digital users. Our personal information has been marketed, auctioned, and monetized in an ever-increasingly exploitative manner to advertisers and political groups, which use it to micro-target and manipulate consumers or voters. Decentralized platforms offer a unique opportunity to weave the privacy principles of the early internet back into the fabric of the emerging web3 ecosystem. xx messenger is dedicated to protecting and strengthening inalienable privacy rights at the dawn of web3.
- Existing Message Encryption is not Quantum Resistant: There is general agreement that, within the relevant timeframe, quantum computers will be able to decode communications that have been encrypted using legacy crypto. At that point, messages sent on all other existing messengers, even those with “strong end-to-end encryption,” will be easily retroactively decoded and analyzed by artificial intelligence. Only what has been said using xx messenger will remain private.
- Only xx Offers Metadata Shredding: All existing mainstream messengers can capture and potentially exploit metadata. Metadata shredding works by sending messages through randomly chosen xx network nodes around the world. Each node changes the order and the encryption before forwarding and then erases any record of what it has done. Each part of the metadata about who is talking to whom is thereby destroyed before any of the parts can even be assembled to trace.
- Full xx Decentralization: Every message sent on xx messenger travels through five nodes chosen at random from hundreds of xx nodes around the world. There is no centralized entity for governments to coerce, no company to insert spyware or reveal data from its database. The xx network supporting the xx messenger is a distributed, decentralized blockchain, now in mainnet, and is operated on transparent software run by more than 350 independently owned nodes in more than 80 countries. The xx messenger App, is truly a decentralized App (dApp), which means that it operates on a decentralized blockchain autonomously through smart contracts.
The pioneering team behind the creation of the xx messenger developed early practical, anonymous, and verifiable cryptographic systems and is led by renowned cryptographer David Chaum, who proposed and deployed digital currencies, mix networks, permissionless cryptographic solutions, and verifiable voting systems starting in the 1980s.
“Recent privacy concerns have sensitized the public to problems with control of personal information by centralized entities like Facebook. Realizing that their information is being misused by corporate entities, people are now trying to understand how to use cryptography and smartphones to protect themselves and change society in beneficial ways; xx messenger is securely decentralizing private communication the way Bitcoin decentralized finance. Let’s do this right: let’s take control of our own information– and our destiny.” said David Chaum, inventor of electronic cash and founder of xx network.
About xx network
xx network is a new type of platform, offering a protected digital sphere through which its users can share ideas and exchange value in a secure and private way. The xx network blockchain relies on a novel quantum-secure consensus algorithm that efficiently achieves linear authenticator complexity and single-block finality, ensuring scaleable consensus-based operations. The network was built by teams led by David Chaum, the Godfather of cryptocurrency.
For more information, please visit https://xx.network/.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
About Business Wire
(c) 2018 Business Wire, Inc., All rights reserved.
Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Takeda and Seagen to Highlight ADCETRIS ® Combination Data Showing Statistically Significant Improvement in Overall Survival (OS) for Patients with Advanced Hodgkin Lymphoma26.5.2022 23:25:00 CEST | Press release
Takeda Pharmaceutical Company Limited (TSE:4502) and Seagen Inc., (NASDAQ:SGEN) today announced that overall survival (OS) data from the Phase 3 ECHELON-1 clinical trial of an ADCETRIS® (brentuximab vedotin) plus chemotherapy combination will be presented in an oral session at the 59th American Society of Clinical Oncology (ASCO) Annual Meeting on Friday, June 3, 2022, 1:00-4:00 PM CT, and at the 27th European Hematology Association (EHA) Annual Meeting on Friday, June 10, 2022, 11:30 – 12:45 CEST. “The longer-term follow-up data from the ECHELON-1 trial have significant clinical importance, as this trial represents one of only two frontline randomized studies in advanced stage Hodgkin lymphoma that shows an overall survival advantage for the experimental arm,” said Stephen Ansell, M.D., Ph.D., Mayo Clinic, and ECHELON-1 study investigator. “These results clearly show that the addition of brentuximab vedotin to chemotherapy improves the long-term outcome of patients and the combination
Ipsen: ASCO 2022: New Cabometyx ® Data Show Encouraging Results in Monotherapy and in Combination Across Different Tumor Types Including Metastatic Non-Small Cell Lung Cancer26.5.2022 23:00:00 CEST | Press release
Regulatory News: Ipsen (Euronext: IPN; ADR: IPSEY) today announced encouraging data to be presented for the multi-targeted tyrosine kinase inhibitor (TKI), Cabometyx® (cabozantinib), across a range of cancer types at this year’s American Society of Clinical Oncology Annual Meeting (ASCO 2022) to be held on 3-7 June. Data presentations will include findings in metastatic non-small cell lung cancer (NSCLC), as well as established indications of advanced renal cell carcinoma and radioactive iodine-refractory differentiated thyroid cancer (RAI-R DTC). These data show that the therapeutic potential of Cabometyx as a key treatment option in a broad range of tumors is continuing to be realized. Updated outcomes from the multicenter Phase Ib COSMIC-021 trial evaluating the combination of Cabometyx plus atezolizumab in an expanded patient population in metastatic NSCLC demonstrate encouraging clinical activity with manageable toxicity in people previously treated with an immune checkpoint inhib
New Better Dispensing Videos from Nordson EFD Explain Jetting Technology and How to Choose the Right Solution26.5.2022 19:00:00 CEST | Press release
Nordson EFD, a Nordson company (NASDAQ: NDSN) and leading precision fluid dispensing systems manufacturer, introduces a new Better Dispensing™ How-To Video series. These three highly educational videos presented by EFD application specialist, Tom Muccino, provide best practices for choosing between contact dispensing and non-contact (jet) dispensing, and how to select the best jetting valve for a manufacturing application. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220510006079/en/ xQR41 Series MicroDot™ needle valve (left) and PICO Pµlse XP jet valve (right). (Photo: Business Wire) “One of the main differences is that with jetting, your valve never touches the surface of the part. Instead, your fluid “flies” or “jets” out of the valve, which is above the part,” Muccino explains in the first video. “This makes jetting perfect for fragile or complex parts.” Nordson EFD provides a wide range of contact and non-contact (jet
Medisca Drives Worldwide Access to Thyroid through Distribution License with SUANFARMA26.5.2022 18:17:00 CEST | Press release
On March 16, 2022, Medisca, a global supplier of pharmaceutical ingredients and equipment, entered into an exclusive agreement with SUANFARMA, a European-based manufacturer and distributor of pharmaceutical ingredients, for the global supply and distribution of Thyroid Powder, USP, by leveraging its exclusive partnership with pharmaceutical manufacturer, Sichuan Deebio Pharmaceutical Co., Ltd (Deebio). “Partnering with Deebio in June 2021 was a huge milestone for the pharmaceutical compounding industry as it allowed us to secure and stabilize the supply of high quality Thyroid Powder for the US market,” said Panagiota Danopoulos, Senior Vice President of Global Strategy & Innovation at Medisca. “After going to market, we immediately realized that the demand for Thyroid Powder extended outside of our usual distribution channels to compounding pharmacies,” continued Danopoulos. “And we had the capacity to upscale supply to make this critical ingredient accessible to various markets, chan
Merck to Present Latest Research From Oncology Portfolio at ASCO 202226.5.2022 18:00:00 CEST | Press release
Merck, a leading science and technology company, today announced the latest research representing the Company’s innovative oncology portfolio has been accepted for presentation at this year’s American Society of Clinical Oncology (ASCO) Annual Meeting, June 3-7, 2022. Data encompass Company-sponsored, investigator-sponsored, and external collaboration studies. Abstracts to be shared at the meeting include data for the Company’s licensed medicines BAVENCIO® (avelumab), TEPMETKO® (tepotinib) and ERBITUX® (cetuximab), and its oncology pipeline. The presentations span key tumor types including advanced urothelial carcinoma (UC), advanced renal cell carcinoma (RCC), metastatic non-small cell lung cancer (NSCLC), metastatic colorectal cancer (CRC), and head and neck cancer (SCCHN). “We look forward to coming together with the scientific community at ASCO 2022, where we will share the latest data from our portfolio, which demonstrate our determination to make a real difference in the lives of